Source: NatPharm gears for local production of pharmaceuticals – herald Sunday Mail Reporter THE Government plans to ...

New long-term clinical data for Blueprint Medicines' drug Ayvakit (avapritinib) were presented at the ASH congress in Orlando, reinforcing the treatment's pr ...

Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or ...

Blueprint Medicines, a Sanofi company, today announced updated data reinforcing the clinical efficacy and safety of long-term ...

African leaders and global partners have agreed on a bold 10-year regional vision to redesign how essential health products are financed, produced, and delivered, marking a major step toward ensuring ...

Blueprint Medicines Corp. has disclosed PROTAC compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a cyclin-dependent kinase 4 (CDK4)-targeting moiety potentially useful ...

Jackie is a retired nurse who began experiencing mysterious symptoms, like severe headaches, diarrhea, and itchy rashes, in the late 1990s. About a decade later, her dermatologist noticed spots on her ...

Blueprint Medicines Corporation (NASDAQ:BPMC) is one of the best biotech stocks to invest in now. On June 12, Blueprint Medicines announced new data reinforcing the sustained clinical efficacy and ...

Kate Haviland is CEO of Blueprint Medicines. From the Boston Business Journal. Sanofi is acquiring Blueprint Medicines Corp. and its rare immunology disease treatment, which is already approved in the ...

Shares of Blueprint Medicines Corporation (NASDAQ:BPMC) rose sharply in today's pre-market trading. Sanofi SA (NASDAQ:SNY) announced plans to acquire Blueprint Medicines for $9.5 billion. Blueprint ...

PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...